This is a China news story, published by Yahoo, that relates primarily to the U.S. Food and Drug Administration news.
For more China news, you can click here:
more China newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
major Chinese medical insurance firm. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Eisai news, drug cost news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
treatment LeqembiReuters
•78% Informative
Leqembi is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease.
The drug works by removing a toxic protein called beta amyloid from the brain.
China approved the treatment in January after a standard approval from the U.S. Food and Drug Administration last July .
VR Score
89
Informative language
97
Neutral language
41
Article tone
formal
Language
English
Language complexity
55
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links